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Abstract
Background
The specificity of nucleic acid amplification tests (NAATs) used for early infant diagnosis
(EID) of HIV infection is <100%, leading some HIV-uninfected infants to be incorrectly identi-
fied as HIV-infected. The World Health Organization recommends that infants undergo a
second NAAT to confirm any positive test result, but implementation is limited. Our objective
was to determine the impact and cost-effectiveness of confirmatory HIV testing for EID pro-
grammes in South Africa.
Method and findings
Using the Cost-effectiveness of Preventing AIDS Complications (CEPAC)–Pediatric model,
we simulated EID testing at age 6 weeks for HIV-exposed infants without and with con-
firmatory testing. We assumed a NAAT cost of US$25, NAAT specificity of 99.6%, NAAT
sensitivity of 100% for infants infected in pregnancy or at least 4 weeks prior to testing, and
a mother-to-child transmission (MTCT) rate at 12 months of 4.9%; we simulated guideline-
concordant rates of testing uptake, result return, and antiretroviral therapy (ART) initiation
(100%). After diagnosis, infants were linked to and retained in care for 10 years (false-posi-
tive) or lifelong (true-positive). All parameters were varied widely in sensitivity analyses. Out-
comes included number of infants with false-positive diagnoses linked to ART per 1,000
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ART initiations, life expectancy (LE, in years) and per-person lifetime HIV-related healthcare
costs. Both without and with confirmatory testing, LE was 26.2 years for HIV-infected infants
and 61.4 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not
differ by strategy. Without confirmatory testing, 128/1,000 ART initiations were false-positive
diagnoses; with confirmatory testing, 1/1,000 ART initiations were false-positive diagnoses.
Because confirmatory testing averted costly HIV care and ART in truly HIV-uninfected
infants, it was cost-saving: total cost US$1,790/infant tested, compared to US$1,830/infant
tested without confirmatory testing. Confirmatory testing remained cost-saving unless
NAAT cost exceeded US$400 or the HIV-uninfected status of infants incorrectly identified
as infected was ascertained and ART stopped within 3 months of starting. Limitations
include uncertainty in the data used in the model, which we examined with sensitivity and
uncertainty analyses. We also excluded clinical harms to HIV-uninfected infants incorrectly
treated with ART after false-positive diagnosis (e.g., medication toxicities); including these
outcomes would further increase the value of confirmatory testing.
Conclusions
Without confirmatory testing, in settings with MTCT rates similar to that of South Africa,
more than 10% of infants who initiate ART may reflect false-positive diagnoses. Confirma-
tory testing prevents inappropriate HIV diagnosis, is cost-saving, and should be adopted in
all EID programmes.
Author summary
Why was this study done?
• Paediatric HIV remains a substantial burden in many low-resource countries, with
170,000 infants infected with HIV in 2015. The World Health Organization (WHO) rec-
ommends virological testing of HIV-exposed infants by 6 weeks of life, with immediate
referral of those who test positive for initiation of HIV care to reduce infant mortality
associated with HIV.
• Despite reported specificities greater than 99%, virological assays still have the possibil-
ity for false-positive diagnoses. The use of confirmatory testing is therefore strongly rec-
ommended in early infant diagnosis (EID) programmes.
• A recent policy survey by WHO demonstrated that implementation of confirmatory
testing in EID programmes is limited, with 38% (8/21) of high-burden countries not
including confirmatory testing for infants in their guidelines.
• Cost is often cited as a key barrier; many low-resource countries struggle to implement
EID programmes due to the high costs of virological tests.
• Our study was designed to estimate the clinical and economic value of confirmatory
testing in EID programmes.
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What did the researchers do and find?
• We used a computer simulation model of paediatric HIV infection, diagnosis, and treat-
ment to examine the clinical and economic outcomes of EID programmes without and
with confirmatory testing in South Africa.
• We found there was no clinical difference in the life expectancy or 1-year survival of
HIV-infected infants between the 2 strategies, but without confirmatory testing, in set-
tings with a mother-to-child transmission (MTCT) rate similar to that of South Africa,
over 10% of infants initiating antiretroviral therapy (ART) would do so inappropriately
as a result of a false-positive diagnosis.
• Confirmatory testing averted costly HIV care and ART in truly HIV-uninfected infants,
leading the confirmatory testing strategy to be cost-saving compared to without confir-
matory testing in all reasonable scenarios.
• ART should be initiated after the first positive test result; when ART was not initiated
until the return of the confirmatory result, mortality during the delay to ART initiation
substantially reduced survival for HIV-infected infants.
What do these findings mean?
• Use of confirmatory testing in EID programmes, with ART initiation after the first posi-
tive result, substantially reduces the proportion of infants incorrectly diagnosed as HIV-
infected and initiated on ART.
• Confirmatory testing is cost-saving under a wide range of scenarios.
• Confirmatory testing should be implemented in settings using virological assays for
EID.
Introduction
Despite the success of programmes to prevent mother-to-child transmission (MTCT) of HIV,
paediatric HIV remains a substantial burden in sub-Saharan Africa, with 170,000 infants
infected with HIV in 2015 [1]. Perinatally infected, untreated infants are at highest risk for
rapid disease progression and mortality, with 1 in 2 untreated HIV-infected infants dying
before their second birthday [2–5]. The World Health Organization (WHO) recommends test-
ing HIV-exposed infants by 6 weeks of life and immediately referring those who test positive
for initiation of HIV care and antiretroviral therapy (ART) [6].
Inexpensive serological antibody assays routinely used for diagnosis in adults cannot be eas-
ily interpreted for HIV-exposed infants (those born to HIV-infected women), because trans-
placental transfer of maternal antibodies leads infants to be seropositive for as long as 18
months [7,8]. Infants therefore require virological tests (nucleic acid amplification tests
[NAATs] detecting HIV RNA or DNA) to diagnose HIV infection [9]. Despite reported speci-
ficities of>99%, NAATs still have the possibility for false-positive diagnoses [10,11]. As the
incidence of paediatric HIV falls with improved access to ART for pregnant/breastfeeding
women, the positive predictive value (PPV) of diagnostic assays also decreases, leading to a
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greater proportion of uninfected infants receiving false-positive diagnoses and starting ART.
After ART is initiated, it may be impossible to distinguish truly infected infants from unin-
fected infants, because effective ART may lead to undetectable HIV RNA in HIV-infected
infants whilst also preventing the development of endogenous anti-HIV antibody after mater-
nal antibody fades from the circulation. Because truly uninfected infants may therefore have
identical laboratory results to treated infected infants, they may face many years or even a life-
time of incorrect diagnosis and ART [7,12,13].
Current WHO and South African guidelines strongly recommend the use of confirmatory
NAAT testing with ART initiation at the first positive result as part of early infant diagnosis
(EID) programmes [6,14]. However, a recent policy survey by WHO demonstrated that
despite confirmatory testing being used routinely for diagnosis of HIV in adults and across
most domains of adult and paediatric medicine, the uptake of confirmatory testing within EID
programmes remains limited, with 38% (8/21) of high-burden countries not including confir-
matory testing for infants in their guidelines [15–17]. Even where guidelines recommend con-
firmatory testing, it is rarely implemented [18]. Cost is often cited as a key barrier; many low-
resource countries struggle to implement EID programmes due to the high costs of the
NAATs required for infant diagnosis. We used a computer simulation model of paediatric
HIV infection, diagnosis, and treatment to examine the clinical and economic outcomes of
EID programmes without and with confirmatory testing in South Africa.
Methods
Overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)–Pediatric model
to simulate a cohort of HIV-exposed infants in South Africa undergoing 2 EID algorithms:
6-week EID testing without confirmatory testing and 6-week EID testing with confirmatory
testing. The CEPAC–Pediatric model is a first-order Monte Carlo simulation model of paedi-
atric HIV infection, disease progression, diagnosis, and treatment [19–21]. For this analysis,
we simulated HIV-exposed infants (born to women living with HIV) from birth through
death. Risk of intrauterine or intrapartum HIV infection was modelled as a 1-time risk, based
on 3 key maternal characteristics: the probability a mother was aware of her HIV diagnosis
during pregnancy; the probability that she received ART during pregnancy, reflecting preven-
tion of MTCT (PMTCT) coverage; and maternal CD4 count for women not receiving ART,
reflecting disease stage. Uninfected infants faced a monthly risk of postpartum transmission
based on these same characteristics until complete cessation of breastfeeding. All simulated
patients faced monthly risks of non-HIV-related mortality. After HIV infection occurred,
patients faced additional risks of opportunistic infections (OIs) and HIV-related mortality
based on their age, CD4 percent (age < 5 years) or CD4 count (age 5 years), retention in
care, and ART use. Full details of the CEPAC–Pediatric model structure are available in S1
Text and S2 Table and at http://web2.research.partners.org/cepac/model.html.
This work was approved by the Partners Human Research Committee, Boston, MA, US.
Modelled population
In the base-case analysis, we simulated HIV-exposed South African children presenting to care
at 6 weeks of age. EID in South Africa is currently directed at infants with known HIV expo-
sure [14]; we therefore included only infants born to women identified as living with HIV dur-
ing pregnancy. South African guidelines currently recommend ‘Option B+’, or lifelong ART
for all pregnant/breastfeeding women identified as living with HIV [14]. We assumed that
90% of women had access to ART during pregnancy and breastfeeding [1]. Based on early data
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after the release of new infant feeding guidelines in South Africa, we assumed 80% of the
cohort was breastfed, for a mean duration of 12 months [6,14,22].
Model outcomes
The model records true infection status for all infants, as well as the results of each adminis-
tered assay, allowing the direct reporting of true-positive, true-negative, false-positive, and
false-negative diagnoses. The primary model outcomes were the number of infants with false-
positive diagnoses linked to care as a proportion of total ART initiations, PPV (defined as the
proportion of positive test results due to truly HIV-infected infants), life expectancy (LE, in
years), and average per-person lifetime HIV-related healthcare costs, from the perspective of
the healthcare provider. We projected survival, LE, and costs separately for HIV-infected
infants and for the complete birth cohort of HIV-exposed infants, which included both HIV-
infected and HIV-uninfected infants. Costs are presented in 2013 US dollars; costs and life
expectancies were modelled both undiscounted and discounted at a rate of 3%/year [23]. We
first calculated per-person outcomes, then translated these to population outcomes for all
350,000 HIV-exposed infants born in South Africa in 1 year [24,25]. Where clinical outcomes
were equal for both strategies, calculation of incremental cost-effectiveness was not necessary;
we considered alternative strategies as either cost-saving or more costly in these cases.
Modelled strategies
The strategy ‘without confirmatory testing’ simulated all HIV-exposed infants receiving a
NAAT at 6 weeks of age; in this strategy, all infants who received positive results initiated ART
upon result return (mean turnaround time: 1 month). The strategy ‘with confirmatory testing’
simulated all HIV-exposed infants receiving a NAAT at 6 weeks of age; all infants who received
positive results on the first test initiated ART at result return, but a second blood sample was
drawn before ART initiation and sent for a confirmatory NAAT [6,14]. We assumed condi-
tional independence of the primary and confirmatory NAAT results, because WHO recom-
mends that a second specimen be used for confirmatory testing, and most false-positive
NAAT results are likely consequences of specimen handling error rather than biological phe-
nomena [6,26,27]. Infants with negative confirmatory tests underwent a third test per WHO
guidelines before HIV infection was ruled out and ART stopped. For infants who were truly
uninfected but initiated ART and therefore entered HIV care after a false-positive diagnosis
(both strategies), we assigned costs for 10 years of routine HIV care, ART, and laboratory
monitoring. We varied this duration widely in sensitivity analysis. For truly infected infants
diagnosed and linked to care, the model includes lifetime costs for routine care, ART, and lab-
oratory monitoring, as well as care for OIs. We conservatively excluded clinical harms from
incorrect ART initiations, such as medication toxicity and stigma.
Input data
We modelled cohort characteristics, PMTCT coverage and MTCT risks, disease progression,
and ART outcomes using data from published trials and cohort studies in sub-Saharan Africa
(Table 1; Table A in S1 Text; S2 Table) [28–32]. The specificity of NAATs was modelled as
99.6%, from a 2015 WHO meta-analysis [33]. We modelled NAAT sensitivity as a function of
time since infection, reaching 100% among infants infected during pregnancy or at least 4
weeks prior to testing (Table 1) [34]. In the base case, laboratory-based NAAT cost was US$25,
which included assays, reagents, and human personnel resources associated with specimen
processing and result return. To describe the full potential impact of each strategy, in the base-
case analysis we modelled guideline-concordant (100%) probabilities of presentation to
Confirmatory testing in early infant diagnosis programmes
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Age, months (SD) 0 (0) — Assumption
Percent male infants 48.8% — [28]
Mothers with CD4 350 cells/μl before ART 36% 30–50 [44]
Breastfeeding (proportion of all infants) 80%a 50–100 [45]
Mean breastfeeding duration, months (SD) 12 (2) 3–18 Assumption
Mother-to-child transmission parameters, percent
Intrauterine/intrapartum—1-time risk
On ART (60% IU transmission; 40% IP transmission) Maternal CD4 350
cells/μl
1.0 ×0.5–2.0 [46–49]
Maternal CD4 > 350
cells/μl
1.0 ×0.5–2.0
Not on ART (60% IU transmission; 40% IP transmission) Maternal CD4 350
cells/μl
27 ×0.5–2.0 [50–55]
Maternal CD4 > 350
cells/μl
17 ×0.5–2.0
Postpartum)—monthly risk during breastfeeding
On ART Maternal CD4 350
cells/μl
0.19 ×0.5–2.0 [56–61]
Maternal CD4 > 350
cells/μl
0.19 ×0.5–2.0
Not on ART—exclusive breastfeeding Maternal CD4 350
cells/μl
0.76 ×0.5–2.0 [44,50,62,63]
Maternal CD4 > 350
cells/μl
0.24 ×0.5–2.0
Not on ART—mixed or complementary feeding Maternal CD4 350
cells/μl
1.28 ×0.5–2.0 [44,50,62,63]
Maternal CD4 > 350
cells/μl
0.40 ×0.5–2.0
PMTCT cascade parameters, percent
Probability maternal status known in pregnancy 100% — Assumption
Probability mother on ART in pregnancy and
breastfeeding
90% 40–100 [1]
Monthly maternal mortality risk Maternal CD4 350
cells/μl
0.21 ×0.5–2.0 CEPAC adult model
Maternal CD4 > 350
cells/μl
0.11 ×0.5–2.0
EID cascade parameters, percent guideline compliant Scenario-specific assumptions
Probability of presenting to a testing visit 100% 0–100
Probability of being offered and accepting test 100% 0–100
Probability of receiving test results 100% 0–100
Delay between primary test and result receipt, months
(SD)
Standard NAAT 1 (0) 0–5
POC NAAT 0 (0) 0–5
Probability of linking to care/ART after diagnosis 100% 0–100
NAAT assay characteristics, base-case percent
Sensitivity of standard NAAT for IU infection All ages 100% 90–100 [33,64]
Sensitivity of standard NAAT for IP infection Month 1 0% — [33,64]
Later months 100% 90–100
Sensitivity of standard NAAT for PP infection (by time
since infection)
Month of infection 0% — [33,64]
Later months 100% 90–100
Specificity of standard NAAT All ages 99.6% 90–100 [33,64]
(Continued )
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testing, result return (first NAAT: 1 month), and ART initiation after an HIV diagnosis; we
varied these widely in sensitivity and scenario analyses to reflect implementation across a
range of settings [1,35–37].
We incorporated published South African healthcare costs for HIV-infected children less
than 5 years of age. Costs associated with OI care for children 5 years of age and older were cal-
culated from South African adult resource utilisation (outpatient visits, inpatient days, and lab-
oratory testing) multiplied by South African unit costs [38,39]. Routine HIV care costs (all
ages) ranged by age from US$20 to US$165 per month [40,41]. First-line ART costs were from
Clinton Health Access Initiative price lists and WHO weight-based dosing recommendations,







Sensitivity of POC All ages 95.5% 90–100 [65,66]
Specificity of POC All ages 99.8% — [65,66]
ART outcomes, percent
ART efficacy: HIV RNA < 400 copies/ml at 24 weeks on
ART
Ages 0–59 months First-line ARTb 91% [29,30]
Second-line ARTc 75%
Ages 60+ months First-line ARTb 75% [67]
Second-line ARTc 75%
ART-associated CD4-independent risk reductions
Risk reduction in OI (age 0–12) 85% [20]
Risk reduction in OI (age 13+) 32% [68]
Risk reduction in mortality (age 0–12) 90% [20]
Risk reduction in mortality (age 13+, range by CD4) 55%–96% [68]
Monthly loss to follow-up after ART initiation 0.2% [29,30]
Costs, US dollars
OI care (per event, range by age, CD4%/CD4, type of
event)
260–2,175 ×0.5–2.0 [39,42,43,69]
Major toxicity event 1,972 ×0.5–2.0 [39]
ART (per month, range by regimen, dose/age) 7–40 ×0.5–2.0 [42,43]
NAAT Standard (laboratory) 25 10–400 Assumption
POC 30 30–50
Negative NAAT result return 1.83 Assumption (nurse
time × salary) [70]
Positive NAAT result return 3.05
Routine HIV care (per month, range by age) 20–165 ×0.5–2.0 [39]
A full description of all model input parameters, as well as ranges for sensitivity analyses and uncertainty analyses, is provided in Tables A and B in S1 Text.
aOf the total population of breastfed infants (80% in the base case), for the first 6 months of life: exclusive breastfeeding in 55%; mixed breastfeeding in
25%; replacement feeding from birth in 20%. After 6 months of age, all infants still breastfeeding are assumed to have complementary feeding (breastmilk
and other liquids/solids).
bLopinavir, ritonavir, abacavir, and lamivudine.
cEfavirenz plus zidovudine and lamivudine.
ART, antiretroviral therapy; CEPAC, Cost-effectiveness of Preventing AIDS Complications; EID, early infant diagnosis; IP, intrapartum; IU, intrauterine;
NAAT, nucleic acid amplification test; OI, opportunistic infection; PMTCT, prevention of mother-to-child transmission; POC, point-of-care; PP, postpartum;
SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002446.t001
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Sensitivity analyses
Following ISPOR–SMDM Good Research Practices Task Force (S1 Table) guidelines on
uncertainty in model-based analyses, we conducted extensive univariate and multivariate sen-
sitivity analyses (Tables B and D in S1 Text) [71]. We first conducted univariate sensitivity
analyses, in which we varied NAAT specificity and sensitivity, infant HIV prevalence via
PMTCT coverage and MTCT risks, the probability of initiating ART after a positive NAAT
result, the amount of time infants with a false-positive diagnosis spent on ART, the costs of
NAATs, routine HIV care and OI care costs, and ART treatment costs (S1 Table; Task Force
recommendation VI-9). Holding all other parameters at their base-case values, we identified
the threshold value for each parameter at which the comparison between with and without
confirmatory testing would change (S1 Table; Task Force recommendation VI-12). We next
performed multivariate sensitivity analyses to evaluate the impact of simultaneous variation in
multiple parameters (S1 Table; Task Force recommendation VI-10). We also examined the
assumption of conditional independence of the first and confirmatory assays by varying their
specificities simultaneously, and assigned a combination of assay cost, sensitivity, specificity,
result return time, and result return probability to reflect emerging point-of-care (POC) EID
assays (Table 1).
Implementation scenario analyses
We conducted 3 scenario analyses to examine important issues in EID implementation (S1
Table; Task Force recommendation VI-10). First, we simulated lower rates of implementation
of 6-week EID testing incorporating input parameters from current testing and treatment cas-
cades in resource-limited countries. We modelled (a) probability of presenting to testing as
73% and probability of ART initiation as 71% of infants with a positive test result and (b) prob-
ability of presenting to testing as 95% (2016 UNAIDS estimates for EID coverage in South
Africa), probability of result return to caregiver as 80%, and probability of ART initiation as
71% [1,35–37]. Second, we examined programmes offering routine EID testing at both birth
and 6 weeks of age to all HIV-exposed infants. Birth tests were modelled as standard labora-
tory-based NAAT tests with a 1-month result return time (Table 1). Third, WHO strongly rec-
ommends prompt ART initiation after a first positive test result (as in our base-case analysis)
to avoid delays during a period of high mortality without treatment, but that NAAT testing be
repeated on a second specimen drawn prior to ART initiation, to confirm the initial diagnosis
[6,7]. Because some providers may be reluctant to initiate ART before receiving a confirmatory
result, we also examined the impact of postponing ART until return of the confirmatory test
result (1–2 months).
Uncertainty analyses
The univariate sensitivity analyses described above reveal the sensitivity of policy conclusions
to variations in key parameters through a wide range of plausible values. To reflect the uncer-
tainty in the primary data estimates, we also varied key parameters through reported 95% con-
fidence intervals (or range or interquartile ranges, if 95% confidence intervals were not
available; S1 Table; Task Force recommendations VI-6 and VI-7). For most parameters, this
interval fell well within the range examined in sensitivity analyses. We used the results of previ-
ously reported model calibration and validation analyses [19,20] to examine the impact of
parameter and model structural uncertainty on the comparison between without and with
confirmatory testing (S1 Table; Task Force recommendation VI-14).
Confirmatory testing in early infant diagnosis programmes
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Results
Base-case results: Clinical outcomes
In the base-case analysis, the birth cohort was projected to include 1.8% infants with intrauter-
ine HIV infection, 1.2% with intrapartum infection, and 1.9% with postpartum infection
(cumulative MTCT risk 4.9%), with 95.1% of the cohort HIV-exposed but uninfected
(Table 2). In both 6-week EID algorithms (without and with confirmatory testing), HIV-
infected infants had a projected 1-year survival of 75.7% and LE of 26.2 years; there was also
no clinical difference between the 2 strategies for the entire birth cohort (1-year survival
93.3%, LE 61.4 years). Without confirmatory testing, 128 infants of every 1,000 who initiated
ART were truly uninfected, reflecting false-positive diagnosis; this led to a PPV of 87.2%. With
confirmatory testing, this proportion fell to only 1 in 1,000 ART initiations, for a PPV of
99.9%.
Base-case results: Costs and cost-savings
Lifetime costs of HIV-exposed infants were US$1,830/infant without confirmatory testing and
US$1,790/infant with confirmatory testing (Table 2; Fig 1). The approach of using confirma-
tory testing was therefore equally effective and was cost-saving; it became cost-saving 3 months
after ART initiation (Fig A in S1 Text). Without confirmatory testing, 2.1% of total lifetime
HIV-related costs for the birth cohort were accrued by truly uninfected infants after false-posi-
tive diagnoses, compared to only 0.01% of lifetime costs with confirmatory testing (Fig 1,
orange). If 6-week EID programmes were available for the 350,000 HIV-exposed infants born
annually in South Africa, 11,000 infants would require a second NAAT to confirm a first posi-
tive result. The cost of these confirmatory NAATs would be approximately US$260,000, but
they would avert unnecessary HIV care and ART for 1,400 infants. By averting unnecessary
ART and HIV costs for uninfected infants, confirmatory testing would save over US$1,050,000
Table 2. Base-case model results: Early infant HIV diagnosis testing at 6 weeks in South Africa with and without confirmatory testing.
a. Clinical outcomes
HIV infected infants Birth cohort
MTCT outcomes
4.9% of entire birth cohort: 1.8% IU, 1.2% IP, 1.9% PP 4.9% HIV-infected 95.1% HIV-exposed uninfected
Clinical outcomesa





EID strategy Number of infants with false-positive
diagnoses initiating ART per 1,000
ART initiations
Lifetime cost per HIV-
exposed infant (US
dollarsb
Proportion of total lifetime costs







128 $1,830 2.1% 87.2%
6-week EID with
confirmatory testing
1 $1,790 0.01% 99.9%
aResults are shown for both strategies. We simulate ART initiation after the first positive EID assay result is received, with ART cessation if a confirmatory
assay is subsequently negative. Because HIV-infected infants do not delay ART initiation for a confirmatory test result, the projected life expectancy for both
EID strategies is equal.
bCosts are in 2013 US dollars and are undiscounted.
ART, antiretroviral therapy; EID, early infant diagnosis; IP, intrapartum; IU, intrauterine; MTCT, mother-to-child transmission; PP, postpartum.
https://doi.org/10.1371/journal.pmed.1002446.t002
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in the first year and US$13,860,000 in lifetime costs for a South African birth cohort, compared
to the approach of not using confirmatory testing [24,25].
Univariate sensitivity analyses: Costs
The use of confirmatory testing remained cost-saving even with wide variations in model
parameters, including the cost, specificity, and sensitivity of the NAAT; the probability of pre-
sentation at each step in the EID cascade; and the costs of routine care and OI care. Robustness
of model results to these key parameters is shown in Fig 2. However, there were 3 key excep-
tions: confirmatory testing was no longer cost-saving if the duration spent by HIV-uninfected
infants in care and on ART after false-positive diagnosis was <3 months (Fig A in S1 Text), if
the first and confirmatory assays were no longer considered to be independent (specificity of
confirmatory assay<15%; Tables D and E in S1 Text), or if the cost of the NAAT was 16-fold
higher than in the base case (>US$400).
Fig 1. Total lifetime costs per HIV-exposed infant by EID strategy. Columns include components of lifetime total costs
per HIV-exposed infant tested: routine HIV care, CD4 and HIV viral load monitoring, OIs and end-of-life care, ART, EID
costs, and false-positive costs. EID programme costs are shown in blue and comprise 2%–3% of lifetime costs, as shown
previously [21]; false-positive costs are shown in orange and are made up of all component costs acquired for HIV-
infected infants other than OI costs. ART, antiretroviral therapy; EID, early infant diagnosis; FP, false-positive; OI,
opportunistic infection.
https://doi.org/10.1371/journal.pmed.1002446.g001
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We repeated the base-case analysis using a NAAT specificity of 98.8%, as reported by WHO
in a previous meta-analysis [33]. The cost-savings associated with confirmatory testing were
greater than in the base case (US$1,900/infant without confirmatory testing; US$1,790/infant
with confirmatory testing; Fig 1; Table C in S1 Text). With this lower specificity, false-positive
diagnoses accounted for 6.0% of total lifetime costs without confirmatory testing, compared to
0.1% with confirmatory testing. After false-positive diagnosis in this scenario, if the HIV status
of infants incorrectly identified as infected could be ascertained and their ART interrupted
within 2 months of starting ART, confirmatory testing would no longer be cost-saving.
Univariate sensitivity analyses: Clinical outcomes
Several variations in model parameters changed the proportion of ART initiations due to
false-positive diagnosis (Table D in S1 Text). Increases in specificity, such as those recently
described for novel POC EID assays, reduced the number of false-positive diagnoses in the
approach without confirmatory testing to 69/1,000 ART initiations (Table D in S1 Text; Fig 3)
[65,66]. A reduction in NAAT sensitivity of 5% only minimally increased the number of
infants initiating ART after false-positive diagnosis without confirmatory testing (from 128/
1,000 ART initiations in the base case to 133/1,000), but LE for HIV-infected infants was
Fig 2. Univariate sensitivity analyses examining the impact of variation in individual input parameters on the difference in
cost per HIV-exposed infant between the without and with confirmatory testing strategies. Key parameters varied in sensitivity
analyses are shown on the left. Values in parentheses indicate the range examined (from the value leading to the lowest difference in
cost to the value leading to the greatest difference, with base-case values after the semicolon). The horizontal axis shows the
difference in cost between the 2 strategies: without confirmatory testing minus with confirmatory testing. The bounds of the blue bar
indicate the cost differences at the extreme parameter values; longer bars therefore indicate parameters to which the model results
were more sensitive. Where confidence intervals were available for the primary data estimates used in the base case, we indicate the
bounds of these confidence intervals with brackets overlying the blue bars; the distance between brackets therefore indicates the
degree to which the base-case estimates are affected by parameter uncertainty. The blue bar reaches the far left axis (indicating a
cost difference of 0) at the threshold value for each parameter where confirmatory testing is no longer cost-saving compared to without
confirmatory testing. The grey vertical line indicates the value for each parameter at the base-case result: a savings of US$40 per
infant with confirmatory testing. ART, antiretroviral therapy; EID, early infant diagnosis; NAAT, nucleic acid amplification test.
https://doi.org/10.1371/journal.pmed.1002446.g002
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reduced to 25.9 years without confirmatory testing and to 25.7 years with confirmatory testing
(Table D footnote in S1 Text). Reductions in the number of infected infants successfully
undergoing EID testing, receiving test results, and initiating ART had minimal effects on the
proportion of ART initiations due to false-positive diagnoses, but reduced the LE for HIV-
infected infants: if only 50% of infected infants completed the EID cascade, LE for HIV-
infected infants was reduced to 23.6 years (Table D in S1 Text).
Multivariate sensitivity analyses
In multivariate sensitivity analyses, results were also sensitive to reductions in NAAT specific-
ity and infant HIV prevalence (lower MTCT risks), as depicted in Fig 4. When MTCT risks
were<1.3% and NAAT specificity was 98.0%, 749/1,000 infants initiating ART without
Fig 3. Number of infants linked to ART after false-positive diagnosis, per 1,000 ART initiations, by
assay specificity. (A) Univariate sensitivity analysis varying NAAT specificity without and with confirmatory
testing for 6-week EID testing. The vertical axis depicts the number of infants with a false-positive diagnosis
who initiate ART, per 1,000 ART initiations. The horizontal axis depicts the specificity of the NAAT. (B) The
inset panel depicts results at higher specificity values, as reported for most NAATs (Table 1). ART,
antiretroviral therapy; EID, early infant diagnosis; NAAT, nucleic acid amplification test.
https://doi.org/10.1371/journal.pmed.1002446.g003
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confirmatory testing were truly uninfected (Fig 4; Table F in S1 Text). With a very high MTCT
risk of 9.6% and NAAT specificity of 99.8%, this fell to 34/1,000 ART initiations without con-
firmatory testing. In all multivariate sensitivity analyses varying specificity (<100%) and infant
HIV prevalence, confirmatory testing remained cost-saving (Table F in S1 Text).
Implementation scenario analyses
Incorporating input parameters from current testing and treatment cascades reduced the LE
of HIV-infected infants, but the number of infants with a false-positive diagnosis initiating
ART remained 128/1,000 ART initiations (Table 3). For programmes offering EID at both
birth and 6 weeks of age, the proportion of infants initiating ART after false-positive diagnosis
without confirmatory testing increased to 213/1,000 ART initiations, accounting for 4.0% of
total costs (Table D and Fig B in S1 Text). When ART was not initiated until the return of the
confirmatory NAAT result, mortality during the delay to ART initiation reduced the projected
1-year survival (74.8%) and LE (25.9 years) for HIV-infected infants with confirmatory testing;
Fig 4. Number of infants linked to ART after false-positive diagnosis, per 1,000 ART initiations, by assay specificity and MTCT risk.
Multivariate sensitivity analysis varying specificity of the NAAT and infant HIV prevalence modelled by increasing MTCT risk. The vertical axis shows
the number of infants with false-positive diagnosis initiating ART, per 1,000 ART initiations. Groups of coloured bars indicate 3 values for infant HIV
prevalence at weaning (12 months of age): purple indicates a low MTCT risk scenario, with 12-month risk of 1.3%; green indicates the base-case value
of 4.9%; and blue indicates a high MTCT risk scenario, with risk of 9.6%. Three values of NAAT specificity are shown within each MTCT risk scenario.
For each combination of MTCT risk and NAAT specificity, bars indicate those who are truly HIV-uninfected (false-positive diagnosis). The left, dark-
coloured bar in each pair reflects the outcome without confirmatory testing, and the right, light-coloured bar reflects the outcome with confirmatory
testing. ART, antiretroviral therapy; EID, early infant diagnosis; MTCT, mother-to-child transmission; NAAT, nucleic acid amplification test.
https://doi.org/10.1371/journal.pmed.1002446.g004
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results for the approach without confirmatory testing (1-year survival 75.7%; LE 26.2 years)
were unchanged (Table D in S1 Text). HIV-related healthcare costs remained lower with con-
firmatory testing than without confirmatory testing in all 3 scenarios.
Uncertainty analyses
The impact of varying key parameters through the confidence intervals around base-case esti-
mates is shown in Fig 2. In all parameter sets derived from formal calibration analyses, confir-
matory testing remained cost-saving (Fig C in S1 Text).
Discussion
We simulated EID strategies without and with confirmatory testing for HIV-exposed infants
in South Africa. The primary finding was that, when confirmatory testing was not used in the
model, more than 10% of infants who initiated ART reflected false-positive diagnoses. These
model results are comparable to empirical data from Africa: when records of infants receiving
positive EID results and/or initiating ART were reviewed in detail, the proportion found to be
truly HIV-uninfected was 2.5% in Kenya, 6.3% in South Africa, 14.6% in Malawi, and 16% in
Coˆte d’Ivoire and Burkina Faso [72–75]. HIV-uninfected infants incorrectly initiating ART
not only receive unnecessary medication exposure and treatment costs, but may also experi-
ence long-term medication toxicities and the substantial stigma associated with HIV diagnosis
[7]. To remain conservative, we did not include these detriments in our analysis. Confirmatory
testing would therefore prevent a broader set of adverse outcomes than those described here in
a substantial proportion of HIV-uninfected infants.
False-positive results occur for a variety of reasons but are likely the result of stretched
human resources compromising test specificity and sensitivity via specimen handling errors
such as mislabelling of specimens, incorrect specimen placement in the device, or inadequate
quality control resulting in contamination between specimens during PCR amplification
[27,76]. WHO recommends the use of a second specimen for a confirmatory test, ensuring the
Table 3. Implementation scenario model results: Early infant HIV diagnosis testing at 6 weeks in South Africa with and without confirmatory
testing.
EID strategy Life expectancy (HIV-
infected infants,
years)
Number of infants with false-
positive diagnoses initiating ART
per 1,000 ART initiations
Proportion of total lifetime costs





95% presentation to EID,
100% result return, 71%
ART initiation
With confirmatory testing 24.6 1 0.006% $1,685
Without confirmatory testing 24.6 128 1.5% $1,710
95% presentation to EID,
80% result return, 71% ART
initiation
With confirmatory testing 23.8 1 0.004% $1,630
Without confirmatory testing 23.8 128 1.2% $1,650
73% presentation to EID,
100% result return, 71%
ART initiation
With confirmatory testing 23.7 1 0.005% $1,620
Without confirmatory testing 23.7 128 1.2% $1,640
ART, antiretroviral therapy; EID, early infant diagnosis.
https://doi.org/10.1371/journal.pmed.1002446.t003
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independence of the 2 assays and reducing the likelihood of a second false-positive result.
Ensuring that an initial HIV diagnosis is correct is essential because identifying a misdiag-
nosed, truly HIV-uninfected infant remains extremely difficult after ART is initiated [6]. Lack
of detectable anti-HIV antibody, HIV RNA, or HIV DNA may reflect either absence of true
infection or the impact of effective ART, which makes withdrawal of treatment the only mech-
anism available for clinicians wishing to determine the true HIV status of an infant on ART.
However, treatment interruptions are not currently recommended, due to concerns about
viral rebound and disease progression [77,78]. Unconfirmed EID test results therefore cause
diagnostic dilemmas for the provider, whilst families may experience confusion and uncer-
tainty about the health system, discouraging future engagement in care [79].
The second key finding from this analysis is that including confirmatory testing in EID pro-
grammes is cost-saving. We found that confirmatory testing reduced the cost per HIV-exposed
infant tested from US$1,830 to US$1,790. Although concerns have been raised about the
capacity of laboratories to conduct the additional assays needed for confirmatory testing, we
found that the number of additional tests was relatively small, as they are required by only 3%
of HIV-exposed infants [9]. The costs of these additional tests to confirm HIV infection would
be offset by the reduction in false-positive diagnoses and their associated unnecessary HIV
care, ART, and ART toxicity costs. Infants with a false-positive diagnosis only had to remain
in care and on ART for longer than 3 months for confirmatory testing to become cost-saving;
a shorter duration on ART would be extremely unlikely due to the difficulty of identifying
uninfected infants after ART initiation. Confirmatory testing remained cost-saving despite
wide variations in the costs of clinical care and ART, and at any plausible NAAT cost. In addi-
tion, our findings demonstrate that confirmatory testing is cost-saving even with increases in
the probability of becoming lost to follow-up between presenting to EID testing, receiving test
results, and initiating ART, but lowering the number of HIV-infected infants initiating ART
reduces LE for truly infected infants.
A third key finding of this analysis is that when confirmatory testing is done, ART should
be initiated after the first positive result, as WHO recommends. If ART was delayed until the
result of the confirmatory assay was available, short-term survival and LE were markedly
reduced. Waiting even 1 month to initiate ART until the return of the confirmatory result can
reduce 1-year survival for HIV-infected infants substantially (from 75.8% to 74.5%) and overall
LE for HIV-infected infants (from 26.2 years to 25.9 years). Novel POC EID assays, which
offer in-clinic testing and same-day result return, have been proposed as an approach to
improving timely ART initiation. Based on preliminary published values for POC NAAT sen-
sitivity (95.5%), specificity (99.8%), and cost (US$30), our analyses suggest that confirmatory
testing would likely remain cost-saving in EID programmes using POC assays in place of tradi-
tional laboratory assays [65,66].
In South Africa, access to ART during pregnancy has steadily increased, leading to a 76%
reduction in new HIV infections among children [1]. If PMTCT programmes continue their
success, MTCT rates will fall below 2%, as they have in countries such as Thailand and Cuba
[80,81]. As expected, we found that confirmatory testing becomes increasingly critical to
reduce false-positive diagnoses when MTCT risks are very low, due to the reduced PPV of
diagnostic assays at low disease prevalence (Fig 3). This remained true even when NAAT spec-
ificity was extremely high (99.9%). In addition to disease prevalence, assay sensitivity also con-
tributes to PPV. We found that small reductions in NAAT sensitivity, a theoretical result of
maternal and infant ART for treatment and MTCT prevention [82], would only minimally
increase the number of infants initiating ART after false-positive diagnosis, although lower
sensitivity would lead to fewer infected infants being identified and would reduce LE for HIV-
infected infants. Finally, opportunities for false-positive results increase when testing is done
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twice; the inclusion of confirmatory testing within the EID cascade is even more important
when programmes consider the addition of birth testing to a 6-week testing programme.
There were 3 main limitations of the analysis. First, uncertainty exists in all long-term pro-
jections; although our model was calibrated to ensure results match current survival and OI
data, developments in treatment and technology will undoubtedly occur in the coming years
[19,20]. Our model structure does not currently permit formal probabilistic sensitivity analy-
ses; however, we performed extensive univariate and multivariate sensitivity analyses to assess
the impact of uncertainty around all key input parameters, in keeping with international
guidelines [71] (Table G in S1 Text). Confirmatory testing remained cost-saving in a wide
range of evaluated scenarios, unless the unlikely thresholds shown in Fig 2 were met or sur-
passed. Second, while we included all relevant costs for HIV-uninfected infants on ART, we
did not include negative clinical impacts for these patients, such as stigma, morbidity or mor-
tality related to ART toxicity, or reduced quality of life after false-positive diagnosis. Including
such harms from false-positive diagnosis would further improve the value of confirmatory
testing. Finally, this work primarily addresses HIV-exposed infants in South Africa, although
our findings may be generalisable to a range of settings: sensitivity analyses demonstrated that
confirmatory testing remained cost-saving even with wide variations in MTCT risk, NAAT
specificity and sensitivity, NAAT costs, and costs for HIV care and ART.
In summary, we find that use of a second NAAT for confirmatory testing in EID pro-
grammes substantially reduces the proportion of infants incorrectly diagnosed as HIV-infected
and initiated on ART. While projected cost differences are small, confirmatory testing is cost-
saving under a wide range of scenarios in South Africa. Confirmatory testing with ART initia-
tion at the first positive result, as recommended by WHO for EID, should be implemented in
settings using NAAT for EID.
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